FDA to review Sanofi and Regeneron’s Dupixent sBLA for bullous pemphigoid
As Sanofi and Regeneron await the FDA decision, a legal dispute between the partners over commercialisation details continues.
Dupilumab Gets Priority Review for Bullous Pemphigoid
Dupilumab, an interleukin-4 receptor antagonist, is expected to decrease the type 2 inflammation seen in bullous pemphigoid.
US FDA accepts for priority review Sanofi & Regeneron’s Dupixent sBLA for the targeted treatment of bullous pemphigoid
US FDA accepts for priority review Sanofi & Regeneron’s Dupixent sBLA for the targeted treatment of bullous pemphigoid: Paris Wednesday, February 19, 2025, 12:00 Hrs [IST] The U
Dupixent® (dupilumab) sBLA Accepted for FDA Priority Review for the Targeted Treatment of Bullous Pemphigoid (BP)
If approved, Dupixent would be the first and only targeted medicine to treat BP in the U.S.; FDA decision expected by June 20, 2025Priority
FDA accepts Dupixent sBLA for priority review in bullous pemphigoid
The US Food and Drug Administration (FDA) has accepted for priority review the supplemental biologics license application (sBLA) for Dupixent (dupilumab) to treat adults with bullous pemphigoid (BP).
sBLA for Dupixent Accepted by FDA for Priority Review
The US Food and Drug Administration (FDA) has accepted for priority review Sanofi’s supplemental biologics license application (sBLA) for Dupixent (dupilumab) to treat adults with bullous pemphigoid (BP), a chronic, debilitating, and relapsing skin disease with underlying type-2 inflammation that typically occurs in an elderly population
Press Release: Dupixent sBLA accepted for FDA priority review for the targeted treatment of bullous pemphigoid
Dupixent sBLA accepted for FDA priority review for the targeted treatment of bullous pemphigoidIf approved, Dupixent would be the first and only
Hosted on MSN4mon
FDA Approves Dupixent Injections For People Struggling With COPD Symptoms
The U.S. Food and Drug Administration (FDA) has approved Dupixent (dupilumab) injections as an add-on therapy for adults with chronic obstructive pulmonary disease (COPD) who continue to struggle ...
Daily2d
Dupilumab significantly Reduces COPD Exacerbations in Phase 3 Trials
Researchers have found in a phase 3 trials that Dupilumab significantly reduced moderate or severe COPD exacerbations ...
Healio23d
Dupilumab does not desensitize children with peanut allergy
Following receipt of dupilumab for 24 weeks, desensitization to peanut exposure in most children/adolescents with peanut allergy was not achieved, according to study results. Image: Adobe Stock ...
The Lancet5d
Patient in her 70s with COPD and asthma improving significantly since using monoclonal antibody dupilumab
Lyn Iemma, aged 75 years at the time of writing, would not describe her life as dramatic. Born and raised in Perth, WA, Australia, this thriving but relaxed city is the place she has always called ...